Eudragit RL100

An attempt was made to formulate and evaluate the Nebivolol HCl transdermal drug delivery system. The matrix type films were prepared by using solvent casting technique with polymers HPMC 15cps,PVP K-30,Eudragit RL100 and Methyl cellulose 15cps.Propylene glycol was used as plasticizer. The prepared films were evaluated for physicochemical characteristics such as thickness, weight variation, folding endurance, % moisture uptake and % moisture loss. The drug excipient compatibility was determined by Fourier Transform Infra red Spectroscopy. The results revealed that there were no interaction between drug and selected polymers. In vitro permeation studies were performed in Franz diffusion cell using commercial semi permeable membrane. Ex vivo studies were performed using skin of albino rats. Biological studies such as skin irritation test and % drug diffusion studies were carried out by using rabbits. Drug content varied from 73.72 ± 0.1to 95.4±0.15%. Moisture content and moisture uptake were increased for patches containing higher amount of HPMC due to its hydrophilic nature. The batch F4 (HPMC 1.5%, PVP 0.5%) had shown drug release for 24 h to the extent of 86.87% and drug release followed zero order release kinetics which was of non-Fickaian type of diffusion. The results of ex vivo and in vivo studies were well correlated with in vitro diffusion studies

  The purpose of this research work was to develop and evaluate matrix-type transdermal therapeutic system containing Losartan potassium (LP) with different ratios of hydrophilic and hydrophobic polymeric combinations. Formulations were prepared by using solvent evaporation technique. Matrix type transdermal film of Losartan Potassium, antihypertensive drug were prepared using different polymers like Ethyl Cellulose, Hydroxy Propyl Methyl Cellulose and Eudragit RL100 in varied ratios. The present study aims to formulate and evaluate Transdermal film for sustained release of Losartan potassium. The results suggested no physicochemical incompatibility between the drug and the polymers. All formulations carried dimethyl sulfoxide as penetration enhancer and propylene glycol as plasticizer in chloroform and ethanol as solvent system. The diffusion studies were performed by using modified Franz diffusion cells. The formulation, F1 with combination of polymers (4:1) emerging to be ideal formulations for Losartan potassium. The developed transdermal films increase the efficacy of for the therapy of hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Physicochemical parameters were characterized. The permeability study indicates that the drug is suitable for Transdermal drug delivery. The film were evaluated for various parameters like Thickness, Water-Vapour permeability, Tensile Strength, moisture loss, moisture uptake, film folding endurance , Drug Content, flatness, surface pH, swellability, % elongation, skin irritation and Diffusion studies. The films were further evaluated by DSC to ensure uniform distribution of the drug and compatibility of drug with polymer. The Optimized formulation containing HPMC: Eudragit RL100 (4:1), with enhancer DMSO showed 87.13% drug release after 24 hours.